Report Detail
Global Depression Therapeutics Market Insights, Forecast to 2025
- RnM3518334 |
- 12 June, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
Antidepressants are used to treat a wide range of mental disorders, including depression, anxiety, and major depressive disorder. Certain neurotransmitters in the brain exist in chemical form such as dopamine and serotonin, which are responsible for maintaining emotional balance such as mood and behavior.
The global Depression Therapeutics market is valued at 12400 million US$ in 2018 and will reach 14700 million US$ by the end of 2025, growing at a CAGR of 2.1% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Depression Therapeutics market based on company, product type, end user and key regions.
This report studies the global market size of Depression Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Depression Therapeutics in these regions.
This research report categorizes the global Depression Therapeutics market by top players/brands, region, type and end user. This report also studies the global Depression Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer, Inc
Eli Lilly and Company
AstraZeneca, Plc
Allergan Plc
GlaxoSmithKline Plc
Intellipharmaceutics International, Inc
Takeda Pharmaceutical Company Limited
H.Lundbeck A/S
Otsuka Holdings Co.,Ltd
Apotex, Inc
Shionogi & Co. Ltd
Zhejiang Hua Hai Pharmaceutical Co., Ltd
Chengdu Kanghong Pharmaceutical Group
Market size by Product
Selective Serotonin Reuptake Inhibitors (SSRIs)
Selective Norepinephrine Reuptake Inhibitors (SNRIs)
Others
Market size by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Depression Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Depression Therapeutics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Depression Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Depression Therapeutics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Depression Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Depression Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Depression Therapeutics Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Depression Therapeutics Market Size Growth Rate by Product
- 1.4.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 1.4.3 Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- 1.4.4 Others
- 1.5 Market by End User
- 1.5.1 Global Depression Therapeutics Market Size Growth Rate by End User
- 1.5.2 Hospital Pharmacies
- 1.5.3 Retail Pharmacies
- 1.5.4 Online Pharmacies
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Depression Therapeutics Market Size
- 2.1.1 Global Depression Therapeutics Revenue 2014-2025
- 2.1.2 Global Depression Therapeutics Sales 2014-2025
- 2.2 Depression Therapeutics Growth Rate by Regions
- 2.2.1 Global Depression Therapeutics Sales by Regions
- 2.2.2 Global Depression Therapeutics Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Depression Therapeutics Sales by Manufacturers
- 3.1.1 Depression Therapeutics Sales by Manufacturers
- 3.1.2 Depression Therapeutics Sales Market Share by Manufacturers
- 3.1.3 Global Depression Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.2 Depression Therapeutics Revenue by Manufacturers
- 3.2.1 Depression Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Depression Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.3 Depression Therapeutics Price by Manufacturers
- 3.4 Depression Therapeutics Manufacturing Base Distribution, Product Types
- 3.4.1 Depression Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Depression Therapeutics Product Type
- 3.4.3 Date of International Manufacturers Enter into Depression Therapeutics Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Depression Therapeutics Sales by Product
- 4.2 Global Depression Therapeutics Revenue by Product
- 4.3 Depression Therapeutics Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Depression Therapeutics Breakdown Data by End User
6 North America
- 6.1 North America Depression Therapeutics by Countries
- 6.1.1 North America Depression Therapeutics Sales by Countries
- 6.1.2 North America Depression Therapeutics Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Depression Therapeutics by Product
- 6.3 North America Depression Therapeutics by End User
7 Europe
- 7.1 Europe Depression Therapeutics by Countries
- 7.1.1 Europe Depression Therapeutics Sales by Countries
- 7.1.2 Europe Depression Therapeutics Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Depression Therapeutics by Product
- 7.3 Europe Depression Therapeutics by End User
8 Asia Pacific
- 8.1 Asia Pacific Depression Therapeutics by Countries
- 8.1.1 Asia Pacific Depression Therapeutics Sales by Countries
- 8.1.2 Asia Pacific Depression Therapeutics Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Depression Therapeutics by Product
- 8.3 Asia Pacific Depression Therapeutics by End User
9 Central & South America
- 9.1 Central & South America Depression Therapeutics by Countries
- 9.1.1 Central & South America Depression Therapeutics Sales by Countries
- 9.1.2 Central & South America Depression Therapeutics Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Depression Therapeutics by Product
- 9.3 Central & South America Depression Therapeutics by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Depression Therapeutics by Countries
- 10.1.1 Middle East and Africa Depression Therapeutics Sales by Countries
- 10.1.2 Middle East and Africa Depression Therapeutics Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Depression Therapeutics by Product
- 10.3 Middle East and Africa Depression Therapeutics by End User
11 Company Profiles
- 11.1 Pfizer, Inc
- 11.1.1 Pfizer, Inc Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Pfizer, Inc Depression Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Pfizer, Inc Depression Therapeutics Products Offered
- 11.1.5 Pfizer, Inc Recent Development
- 11.2 Eli Lilly and Company
- 11.2.1 Eli Lilly and Company Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Eli Lilly and Company Depression Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Eli Lilly and Company Depression Therapeutics Products Offered
- 11.2.5 Eli Lilly and Company Recent Development
- 11.3 AstraZeneca, Plc
- 11.3.1 AstraZeneca, Plc Company Details
- 11.3.2 Company Business Overview
- 11.3.3 AstraZeneca, Plc Depression Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 AstraZeneca, Plc Depression Therapeutics Products Offered
- 11.3.5 AstraZeneca, Plc Recent Development
- 11.4 Allergan Plc
- 11.4.1 Allergan Plc Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Allergan Plc Depression Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Allergan Plc Depression Therapeutics Products Offered
- 11.4.5 Allergan Plc Recent Development
- 11.5 GlaxoSmithKline Plc
- 11.5.1 GlaxoSmithKline Plc Company Details
- 11.5.2 Company Business Overview
- 11.5.3 GlaxoSmithKline Plc Depression Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 GlaxoSmithKline Plc Depression Therapeutics Products Offered
- 11.5.5 GlaxoSmithKline Plc Recent Development
- 11.6 Intellipharmaceutics International, Inc
- 11.6.1 Intellipharmaceutics International, Inc Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Intellipharmaceutics International, Inc Depression Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Intellipharmaceutics International, Inc Depression Therapeutics Products Offered
- 11.6.5 Intellipharmaceutics International, Inc Recent Development
- 11.7 Takeda Pharmaceutical Company Limited
- 11.7.1 Takeda Pharmaceutical Company Limited Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Takeda Pharmaceutical Company Limited Depression Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Takeda Pharmaceutical Company Limited Depression Therapeutics Products Offered
- 11.7.5 Takeda Pharmaceutical Company Limited Recent Development
- 11.8 H.Lundbeck A/S
- 11.8.1 H.Lundbeck A/S Company Details
- 11.8.2 Company Business Overview
- 11.8.3 H.Lundbeck A/S Depression Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 H.Lundbeck A/S Depression Therapeutics Products Offered
- 11.8.5 H.Lundbeck A/S Recent Development
- 11.9 Otsuka Holdings Co.,Ltd
- 11.9.1 Otsuka Holdings Co.,Ltd Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Otsuka Holdings Co.,Ltd Depression Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Otsuka Holdings Co.,Ltd Depression Therapeutics Products Offered
- 11.9.5 Otsuka Holdings Co.,Ltd Recent Development
- 11.10 Apotex, Inc
- 11.10.1 Apotex, Inc Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Apotex, Inc Depression Therapeutics Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Apotex, Inc Depression Therapeutics Products Offered
- 11.10.5 Apotex, Inc Recent Development
- 11.11 Shionogi & Co. Ltd
- 11.12 Zhejiang Hua Hai Pharmaceutical Co., Ltd
- 11.13 Chengdu Kanghong Pharmaceutical Group
12 Future Forecast
- 12.1 Depression Therapeutics Market Forecast by Regions
- 12.1.1 Global Depression Therapeutics Sales Forecast by Regions 2019-2025
- 12.1.2 Global Depression Therapeutics Revenue Forecast by Regions 2019-2025
- 12.2 Depression Therapeutics Market Forecast by Product
- 12.2.1 Global Depression Therapeutics Sales Forecast by Product 2019-2025
- 12.2.2 Global Depression Therapeutics Revenue Forecast by Product 2019-2025
- 12.3 Depression Therapeutics Market Forecast by End User
- 12.4 North America Depression Therapeutics Forecast
- 12.5 Europe Depression Therapeutics Forecast
- 12.6 Asia Pacific Depression Therapeutics Forecast
- 12.7 Central & South America Depression Therapeutics Forecast
- 12.8 Middle East and Africa Depression Therapeutics Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Depression Therapeutics Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Depression Therapeutics . Industry analysis & Market Report on Depression Therapeutics is a syndicated market report, published as Global Depression Therapeutics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Depression Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
